Cargando…

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes

Detalles Bibliográficos
Autores principales:	Holst, Jens J., Knop, Filip K., Vilsbøll, Tina, Krarup, Thure, Madsbad, Sten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2011
Materias:	Diabetes Treatments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632188/ https://www.ncbi.nlm.nih.gov/pubmed/21525464 http://dx.doi.org/10.2337/dc11-s227

Ejemplares similares

Incretin-Based Therapies: Viewpoints on the way to consensus
por: Nauck, Michael. A., et al.
Publicado: (2009)

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report
por: Knop, Filip K, et al.
Publicado: (2014)

Therapy in the Early Stage: Incretins
por: Cernea, Simona, et al.
Publicado: (2011)

Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

Incretin Effects on β-Cell Function, Replication, and Mass: The human perspective
por: Garber, Alan J.
Publicado: (2011)

Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes
por: Mari, Andrea, et al.
Publicado: (2013)

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes
por: Sonne, David P, et al.
Publicado: (2014)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
por: Hansen, Katrine B, et al.
Publicado: (2010)

Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
por: Gluud, Lise L, et al.
Publicado: (2014)

The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial
por: Foghsgaard, Signe, et al.
Publicado: (2013)

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study
por: Dejgaard, Thomas Fremming, et al.
Publicado: (2015)

Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
por: DeFronzo, Ralph A., et al.
Publicado: (2011)

Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: protocol for systematic review and meta-analysis of clinical studies
por: Rohde, Ulrich, et al.
Publicado: (2013)

The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials
por: Storgaard, Heidi, et al.
Publicado: (2014)

Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
por: Lebovitz, Harold E.
Publicado: (2011)

Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial
por: Sidelmann Christensen, Alexander, et al.
Publicado: (2018)

Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial
por: Johansen, Nicklas Järvelä, et al.
Publicado: (2018)

No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect
por: Mathiesen, David S, et al.
Publicado: (2020)

The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial
por: Larsen, Emil List, et al.
Publicado: (2017)

Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials
por: Hansen, Morten, et al.
Publicado: (2012)

Multidrug Treatment of Type 2 Diabetes: A challenge for compliance
por: Miccoli, Roberto, et al.
Publicado: (2011)

Glucokinase Activators for Diabetes Therapy: May 2010 status report
por: Matschinsky, Franz M., et al.
Publicado: (2011)

Role of Bile Acid Sequestrants in the Treatment of Type 2 Diabetes
por: Handelsman, Yehuda
Publicado: (2011)

Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial
por: Helsted, Mads M, et al.
Publicado: (2023)

Long-Term Benefits From Lifestyle Interventions for Type 2 Diabetes Prevention: Time to expand the efforts
por: Tuomilehto, Jaakko, et al.
Publicado: (2011)

Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes
por: Bolli, Geremia B., et al.
Publicado: (2011)

Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet
por: Jensen, Simon Birk Kjær, et al.
Publicado: (2019)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

Glycemic Control Impact on Body Weight Potential to Reduce Cardiovascular Risk: Glucagon-like peptide 1 agonists
por: Sesti, Giorgio
Publicado: (2011)

DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors
por: Dicker, Dror
Publicado: (2011)

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability
por: Garber, Alan J.
Publicado: (2011)

An Outline of the Allen Method
Publicado: (1919)

Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
por: Christensen, Mikkel, et al.
Publicado: (2011)

Weight loss improves β-cell function independently of dietary carbohydrate restriction in people with type 2 diabetes: A 6-week randomized controlled trial
por: Thomsen, Mads N., et al.
Publicado: (2022)

Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes
por: Hansen, Christian Stevns, et al.
Publicado: (2019)

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
por: Subramanian, Vijaya, et al.
Publicado: (2022)

Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial
por: Larsen, Julie Rask, et al.
Publicado: (2014)

What is Diabetes Remission?
por: Holst, Jens J., et al.
Publicado: (2021)

The acute effects of dietary carbohydrate reduction on postprandial responses of non-esterified fatty acids and triglycerides: a randomized trial
por: Samkani, Amirsalar, et al.
Publicado: (2018)

Acute Effects of Dietary Carbohydrate Restriction on Glycemia, Lipemia and Appetite Regulating Hormones in Normal-Weight to Obese Subjects
por: Samkani, Amirsalar, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_medfrd0k7l47q0djervtl83std